high blood pressure 17

Participants: females and Males with either prehypertension (120-139 mm Hg systolic/80-89 mm Hgdiastolic; n = 19; mean age 47.8 [ or -] 3.five years old) or stage 1 hypertension (140-159http://www.bloodpressureuk.org/ mm Hg systolic/90-99 mm Hg diastolic; n = 22; mean age 49.2 [ or-] 2.9 years) were signed up for the investigation. Subjects taking antihypertensive medications wereunacceptable high blood pressure symptoms inside the study.

Study Medication and Dosage: 365 mg of quercetin aglycone b.i.d. (USANA Health Sciences, SaltLake City, Utah) or placebo.

Duration: 30 days of treatment high bloodpressure symptoms with either quercetin orplacebo followed by a 14-day washout phase.This became then cross-over and the other14-day treatment period on either quercetinor placebo. Patients were randomized after aprimary 14-day run-in period.

Outcome Measures: The modification in blood pressure levels (BP) when compared with baselinemeasurement was the principal outcome measure. Secondary outcomes included the result ofquercetin on measures of oxidant stress measured within the plasma and urine. Additionally, bloodsamples were utilized to measure plasma quercetin concentrations along with blood lipidconcentrations (triglycerides, LDL-C, HDL-C, VLDL-C, and total lipoprotein concentrations).

KeyFindings:BPwasnotchanged in prehypertensive patients following supplementation with quercetin nor did it change during theplacebo phase in the study. In stage 1 hypertensive patients, quercetin supplementation significantlyreduced systolic BP (-7 [ or -] 2 mm Hg; p < 0.01), diastolic BP (-5 [ or -] 2 mm Hg; p < 0.01), andmean arterial pressures (-5 [ or -] 2 mm Hg; p < 0.01). The antihypertensive effect of quercetin wasindependent ofgender and age, and BMI in stage 1 hypertensive patients. Indices of oxidative stressin the urine and plasma were unaffected by quercetin in both groups. Also, there was no effect onblood lipid concentrations during quercetin supplementation.

Practice Implications: If quercetin was able to reduce BP in prehypertensive and stage 1hypertensive human subjects, based on the results of animal studies demonstrating the effect ofquercetin on vasorelaxation and blood pressure, researchers from the University of Utah decided tosee. The crossover design of the study suggests that a daily dose of 730 mg of quercetin (in anaglycone form) is capable of reducing both systolic BP and diastolic BP in stage 1 hypertensivepatients but not prehypertensive patients. Hopefully this study will set the stage for future dose-response studies as well as a larger placebo-controlled trial with stage 1 hypertensive patients.